| [1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(1):7-30
|
| [2] |
Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314.
|
| [3] |
中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范（2017年版）[J]．临床肝胆病杂志，2017，33(8):1419-1431.
|
| [4] |
Lu LC, Cheng AL, Poon RT. Recent advances in the prevention of hepatocellular carcinoma recurrence[J]. Semin Liver Dis, 2014, 34(4):427-434.
|
| [5] |
Huang A, Zhao X, Yang XR, et al. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma[J]. J Hepatol, 2017, 67(2):293-301.
|
| [6] |
Guo W, Sun YF, Shen MN, et al. Circulating tumor cells with stem-like phenotypes for diagnosis, prognosis, and therapeutic response evaluation in hepatocellular carcinoma[J]. Clin Cancer Res, 2018, 24(9):2203-2213.
|
| [7] |
Erridge S, Pucher PH, Markar SR, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma[J]. Br J Surg, 2017, 104(11):1433-1442.
|
| [8] |
Nagasue N, Yukaya H, Ogawa Y, et al. Second hepatic resection for recurrent hepatocellular carcinoma[J]. Br J Surg, 1986, 73(6):434-438.
|
| [9] |
Faber W, Seehofer D, Neuhaus P, et al. Repeated liver resection for recurrent hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2011, 26(7):1189-1194.
|
| [10] |
Roayaie S, Bassi D, Tarchi P, et al. Second hepatic resection for recurrent hepatocellular cancer: a Western experience[J]. J Hepatol, 2011, 55(2):346-350.
|
| [11] |
Huang ZY, Liang BY, Xiong M, et al. Long-term outcomes of repeat hepatic resection in patients with recurrent hepatocellular carcinoma and analysis of recurrent types and their prognosis: a single-center experience in China[J]. Ann Surg Oncol, 2012, 19(8):2515-2525.
|
| [12] |
Chan DL, Morris DL, Chua TC. Clinical efficacy and predictors of outcomes of repeat hepatectomy for recurrent hepatocellular carcinoma-a systematic review[J]. Surg Oncol, 2013, 22(2):e23-30.
|
| [13] |
Mise Y, Hasegawa K, Shindoh J, et al. The feasibility of third or more repeat hepatectomy for recurrent hepatocellular carcinoma[J]. Ann Surg, 2015, 262(2):347-357.
|
| [14] |
肖永胜，周俭．肝癌术后复发再治疗方式合理选择[J]．中国实用外科杂志，2016，36(6):627-630.
|
| [15] |
Yamashita S, Aoki T, Inoue Y, et al. Outcome of salvage hepatic resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy[J]. Surgery, 2015, 157(3):463-472.
|
| [16] |
Kow AW, Kwon CH, Song S, et al. Clinicopathological factors and long-term outcome comparing between lung and peritoneal metastasectomy after hepatectomy for hepatocellular carcinoma ina tertiary institution[J]. Surgery, 2015, 157(4):645-653.
|
| [17] |
Hasegawa K, Aoki T, Ishizawa T, et al. Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinoma[J]. Ann Surg Oncol, 2014, 21 Suppl 3:S348-355.
|
| [18] |
Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data[J]. Hepatology, 2016, 64(1):106-116.
|
| [19] |
Choi JW, Park JY, Ahn SH, et al. Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection[J]. Am J Clin Oncol, 2009, 32(6):564-569.
|
| [20] |
Peng ZW, Zhang YJ, Liang HH, et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone:a prospective randomized trial[J]. Radiology, 2012, 262(2):689-700.
|
| [21] |
Galle PR, Tovoli F, Foerster F, et al. The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy[J].J Hepatol, 2017, 67(1):173-183.
|
| [22] |
He J, Zeng ZC, Tang ZY, et al. Clinical features and prognostic factors in patients with bone metastases from hepatocellular carcinoma receiving external beam radiotherapy[J]. Cancer, 2009, 115(12):2710-2720.
|
| [23] |
王征，周俭．肝癌术后复发转移多学科综合治疗[J]．中国实用外科杂志，2014，34(8):723-725.
|
| [24] |
Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28):3501-3508.
|
| [25] |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4):378-390.
|
| [26] |
Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2015, 16(13):1344-1354.
|
| [27] |
Bruix J, Cheng AL, Meinhardt G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies[J]. J Hepatol, 2017, 67(5):999-1008.
|
| [28] |
Finn RS, Merle P, Granito A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial[J]. J Hepatol, 2018, 69(2):353-358.
|
| [29] |
Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial[J]. Gut, 2018, 67(11):2006-2016.
|
| [30] |
刘允怡，赖俊雄，刘晓欣．肝癌术后复发治疗方式合理选择[J]．中国实用外科杂志，2012(10):796-798.
|